[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiovascular-function\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiovascular-function":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100578440","phase-2-effects-of-tirzepatide-on-muscle-and-vascular-health-in-obese-older-adults-100578440",false,"NCT06811324","Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults","The Effects of Tirzepatide Use on Muscle and Vascular Function Among Obese Older Adults","Inclusion Criteria\n\n* Men and postmenopausal women aged 50 years or older.\n* Body Mass Index (BMI) ≥30 kg\u002Fm².\n* Untreated HbA1c \\\u003C6.5% at baseline.\n* Willingness and ability to comply with all study procedures, including fasting requirements for certain visits.\n* Able to provide informed consent and participate in all study assessments.\n\nExclusion Criteria\n\n* Active diagnosis of type 2 diabetes mellitus (T2DM), defined by active use of glucose-lowering medications or hemoglobin A1c ≥ 6.5%.\n* Body Mass Index (BMI) ≥ 40 kg\u002Fm².\n* Moderate to severe gastroesophageal reflux disease based on patient history.\n* Inability to comply with the treatment protocol or to understand the consent form.\n* Chronic Kidney Disease (CKD) Stage 4.\n* Aspartate aminotransferase (AST) \\> 33 U\u002FL or alanine aminotransferase (ALT) \\> 36 U\u002FL.\n* Active pregnancy.\n* Personal or family history of medullary thyroid carcinoma.\n* Personal or family history of multiple endocrine neoplasia type 2 syndrome.\n* Personal history of gastroparesis.\n* Personal history of diabetic retinopathy.\n* Known serious hypersensitivity, including anaphylaxis and angioedema, to Tirzepatide or any of its excipients.\n* Known serious hypersensitivity, including anaphylaxis and angioedema, to any GLP-1 receptor agonist class of therapies.\n* Concomitant treatment with GLP-1 receptor agonist therapy","ALL","50 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Obesity and type 2 diabetes mellitus (T2DM) represent major public health concerns in the aging community. Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist recently approved for the treatment of T2DM and obesity has been shown to be effective at reducing weight, improving markers of T2DM control, and improving cardiovascular health. Utilization of tirzepatide among older adults has been on the rise since FDA approval was issued, however the effects of tirzepatide use on functional outcomes in older adults with obesity are not well established. Recent studies show that weight loss caused by tirzepatide may be driven by substantial loss of lean muscle mass, which may contribute to weakness and frailty, particularly among older adults. The proposed pilot study aims to evaluate how treatment with tirzepatide for 6 months affects muscle mass and function among older adults, and if changes in muscle mass are linked to changes in functional status over the same time period.",[26,27,28,29,30],"Obesity Prevention","Sarcopenia in Elderly","Cardiovascular Function","GLP - 1","Weight Loss",[32,33,34,35,28],"Tirzepatide","GLP-1","Obesity","Sarcopenia","RECRUITING","2026-04-10",{"date":39,"type":40},"2026-04-15","ACTUAL",{"date":42,"type":40},"2026-04-01",{"date":44,"type":20},"2027-06-01",{"name":46,"class":47},"The University of Texas Health Science Center at San Antonio","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":16,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":21,"phases":61,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":48},"100581372","effects-of-exercise-snacks-and-sprint-interval-training-in-overweight-adults-100581372","NCT06849453","Effects of Exercise Snacks and Sprint Interval Training in Overweight Adults","Effects of Exercise Snacks and Sprint Interval Training on Cardiovascular Function in Overweight Adults: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Men and women aged between 18 and 35 years;\n* Overweight but not obese (BMI ≥24 and ≤ 28 kg\u002Fm2);\n* Physically inactive (3 or less bouts of purposeful exercise per week);\n* Ability to understand the research details and voluntarily sign the informed consent form;\n* Non-smoker (for \\>5 years);\n* Body weight has been stable over the past six months, with no recent weight gain or loss behaviors;\n* Healthy (see exclusion criteria).\n\nExclusion Criteria:\n\n* Any chronic illness, cardiac, pulmonary, liver, or kidney abnormalities, uncontrolled hypertension, peripheral arterial disease, insulin- or non-insulin dependent diabetes or other metabolic disorders - all ascertained through preliminary screening;\n* Individuals with a history of bone, joint or neuromuscular problems or a current musculoskeletal injury ascertained through preliminary screening;\n* Abnormal electrocardiogram (ECG) results;\n* Currently taking medication that may affect physiological testing;\n* Contraindications to exercise.",true,"18 Years","35 Years",{"count":60,"type":20},45,[62],"NA","Exploring the efficacy and acceptability of exercise snacks (ES) and sprint interval training (SIT) could provide time-efficient, low-barrier alternatives for individuals, especially those who, due to 'lack of time, environment, and equipment,' struggle to meet traditional physical activity recommendations. This research aims to investigate the effects of ES and SIT, of equal exercise volume, on overweight adults.",[28,65],"Cardiorespiratory Fitness",[67,68,69,28],"Exercise Snacks","Sprint Interval Training","Overweight Adults","NOT_YET_RECRUITING","2025-02-25",{"date":73,"type":40},"2025-02-27",{"date":75,"type":20},"2025-02-24",{"date":77,"type":20},"2025-10-31",{"name":79,"class":47},"Beijing Sport University"]